ORIGINAL RESEARCH article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1592862
Exploration of the Role and Mechanism of Rhizoma Paridis Total Saponins in Osteosarcoma Based on SPI1/LCN2-Mediated Ferroptosis
Provisionally accepted
- 1Department of Pediatric Orthopedics, Children's Hospital Affiliated to Xiangya Medical College of Central South University (Hunan Children's Hospital), Changsha, China
- 2Department of Nursing, Hunan Provincial Rehabilitation Hospital, Changsha, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Osteosarcoma (OS) is a highly aggressive bone malignancy with limited therapeutic options and poor prognosis, particularly in cases of recurrence or metastasis.Recent studies have identified ferroptosis as a promising therapeutic target in OS, with the SPI1/LCN2 regulatory axis emerging as a critical modulator of this process. We hypothesized that Rhizoma Paridis total saponins (RPTS) exert anti-osteosarcoma effects by inducing ferroptosis through inhibition of the SPI1/LCN2 axis.In vitro assessments using OS cell lines MG-63 and Saos-2 included cell counting kit-8 (CCK-8) assays for viability, colony formation for proliferation, scratch wound healing for migration, and Transwell chambers for invasion. Ferroptosis markers were evaluated using colorimetric Fe 2+ detection, flow cytometric apoptosis analysis, DCFH-DA probes for reactive oxygen species (ROS), DTNB colorimetry for glutathione (GSH) levels, and western blot (WB) for SLC7A11 and GPX4 expression.A subcutaneous xenograft mouse model received OS cell injections for in vivo validation of tumor growth parameters and protein expression. Bioinformatics analysis was conducted to screen OS-specific differentially expressed genes, followed by validation in both in vivo and in vitro experiments using RT-qPCR and WB.: RPTS significantly inhibited OS cell viability, proliferation, migration, and invasion capacity while promoting Fe 2+ accumulation and ROS generation. In vivo, RPTS treatment significantly inhibited tumor growth in vivo. Bioinformatics analysis identified LCN2 as the core ferroptosis mediator regulated by upstream transcription factor SPI1. RPTS downregulated SPI1 and LCN2 expression in vitro and in vivo. Both LCN2 overexpression and SPI1 activation reversed RPTS-mediated ferroptosis induction. SPI1 overexpression with LCN2 knockdown attenuated the promoting effect of RPTS on ferroptosis. Conclusion: RPTS triggers ferroptosis-mediated OS suppression through SPI1/LCN2 axis inhibition, providing a novel therapeutic strategy to improve clinical outcomes in OS management.
Keywords: Osteosarcoma, Rhizoma paridis total saponins, ferroptosis, LCN2, SPI1
Received: 13 Mar 2025; Accepted: 11 Jun 2025.
Copyright: © 2025 Yang, Li, Hu, Li, Liu, Zhu and Tan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Qian Tan, Department of Pediatric Orthopedics, Children's Hospital Affiliated to Xiangya Medical College of Central South University (Hunan Children's Hospital), Changsha, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.